Ablynx (ABLYF) Announces Update on Anti-RSV Nanobody Programme and Receives Grant Funding for Further Development
10/31/2013 10:21:14 AM
GHENT, Belgium, Oct. 31, 2013 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels:ABLX] today announced that it has received notice of a €1.68 million in grant funding from the Flemish Agency for Innovation by Science and Technology (IWT) to help advance the Company's first inhaled Nanobody®, ALX-0171, in infants. The grant funding, which is available over a period of one year, will also be used to explore novel applications of nebulised Nanobodies.
Help employers find you! Check out all the jobs and post your resume.
comments powered by